VentriPoint Diagnostics Ltd. (CVE:VPT) Engages Frontier Consulting Ltd.

VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd. (CVE:VPT) has engaged Frontier Consulting Ltd to provide the firm with investor relations services in agreement with regulatory rules to enhance market exposure. Frontier Consulting is a part of the Frontier Merchant Capital Group.

The details

FronTier is a highly recognized and experienced investor relations group, based in Toronto with additional offices and IR executives across the USA and Canada. It will help VentriPoint by increasing market awareness for the firm using different financial market communications measures, the core of which will be supporting in-person introductions for the firm with retail and institutional brokers and shareholders in a number of towns across the US, Europe, Australasia and Canada.

Under the agreement terms, FronTier has been engaged for 12 months to offer IR services for a compensation of $6,000 payable quarterly, and to offer more marketing consulting services for $60,000. VentriPoint issued stock options of 200,000 to FronTier bearing an exercise price of $0.15, conferring in equal quarterly payments over 12 months and closing two years from the grant date. FronTier and its related firms currently own as many as 834,000 common shares of company and common share warrants amounting to 834,000.

In addition, the firm reported a correction to its News Release of December 19, 2016 reporting the closing of the firm’s Private Placement and Shares for Debt in December 2016. Dr. George Adams, the Director and CEO of VentriPoint, had subscribed for only 666,000 Units, and not 660,000 in the second tranche.

Recently, the company received a license for its VMS-PLUS™ machine as well as for the 4C heart analysis system from Health Canada. As a result, now the VMS heart analysis product will also include right atrium, left ventricle and left atrium chambers of the heart.

In the last trading session, the stock price of VentriPoint declined over 24% to close at $0.540.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.